EPSTEIN
page 1 / 366 . OCR, unverified
Dataset92 232
--- SOURCE: 0232__EFTA00669794.txt ---
METADATA_SOURCE: 0232
METADATA_FILENAME: EFTA00669794.pdf
----------------------------------------
From: Richard Kahn
To: "Jeffrey E." <jeevacation@gmail.com>
Subject: Payroll Analysis as of 6-10-2014
Date: Wed, 11 Jun 2014 20:12:12 +0000
Attachments: SHBRK_Scann14061115450.pdf
Richard Kahn
HBRK Associates Inc.
575 Lexington Avenue 4th Floor
New York NY 10022
tel
fax
cell
Begin forwarded message:
From:
Subject: Message from KMBT_C253
Date: June 11, 2014 at 3:45:56 PM EDT
To:
Reply-To:
EFTA00669794
--- SOURCE: 0232__EFTA00669795.txt ---
METADATA_SOURCE: 0232
METADATA_FILENAME: EFTA00669795.pdf
----------------------------------------
From: Boris Nikolic
To: Jeffrey Epstein <jeevacation@gmail.com>
Subject: RE:
Date: Mon, 26 Aug 2013 16:31:51 +0000
Still awaiting.
Will call again.
Sent from my Windows Phone
From: Jeffreylpstein
Sent: 8/26/2013 7:12 PM
To: Boris Nikolic
Subject:
christine?
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to jeevacation®gmail.com, and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA00669795
--- SOURCE: 0232__EFTA00669796.txt ---
METADATA_SOURCE: 0232
METADATA_FILENAME: EFTA00669796.pdf
----------------------------------------
From: Tyler Shears
To: "jeffrey E." <jeevacation@gmail.com>
Subject: Re:
Date: Mon, 16 Jun 2014 20:18:59 +0000
Inline-Images: jeffrey_epsteinn
Google_Search.png; Screen_Shot_2014-06-16_at_3.40.26_PM.png
This is what most will see - you are using your signed in browser
Google Chrome incognito delivers following result. One less negative and things are in different positions
I can tell you are logged in when you check because it says "only you can see these results" in the top right.
W2,Inline image 1
On Mon, Jun 16, 2014 at 3:41 PM, jeffrey E. <jeevacation@gmail.com> wrote:
2,Inline image 1
please note
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
JEE
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
EFTA00669796
--- PAGE 2 ---
communication in error, please notify us immediately by
return e-mail or by e-mail to jeevacation@gmail.com, and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA00669797
--- SOURCE: 0232__EFTA00669798.txt ---
METADATA_SOURCE: 0232
METADATA_FILENAME: EFTA00669798.pdf
----------------------------------------
From:
To: Jeffrey Epstein <jeevaeation@gmail.com>
Subject: Fwd: Neuroscience Proposal
Date: Tue, 27 Aug 2013 02:12:41 +0000
Attachments: LeoneP.CV.8-2013.pdf
Inline-Images: signature[2].png
Forwarded message
From: Leone, Paola
Date: Fri, Aug 23, 2013 at 2:21 PM
Subject: Neuroscience Proposal
To: "jeffrey*jeffreyepstein.org" <jeffreyideffreyepstein.org>
Dear Mr. Epstein,
I am an Associate Professor of Cell Biology at Rowan University-School of Osteopathic Medicine,
where I also direct the Cell & Gene Therapy Center. I am an internationally recognized pioneer in the
field of gene therapy for rare neurogenetic diseases, and spearheaded the first clinical viral gene
therapy application for a neurologic disease.
Your Foundation mission focusing on igniting groundbreaking ideas in the neurosciences compelled
me to contact you. As a visionary science investor in innovative projects ranging from
Cancer,Evolutionary Biology and Late-onset Alzheimer's Disease, you may be interested in evaluating
the importance of my current research that holds considerablepotential for the actual therapeutic
development of Age-related Dementias. The World Health Organization's and Alzheimer's Disease
International's report on Dementia (2012) recognizes that the global burden of Alzheimer Disease (AD)
is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions
that could provide a delay in progression or improvement would provide a significant reduction in
health care burden and cost associated with late or end stage of Alzheimer's and other dementia.
Recent well-publicized reports of the failure of immunotherapeutic agents in Phase-III clinical trials
have highlighted the inadequacy of the "Amyloid Cascade Hypothesis for Alzheimer's Disease" and have
prompted further discussion about current foci for novel clinical application. My current research